Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis

ISSN:
1432-1920
Keywords:
Multiple sclerosis ; Magnetic resonance imaging ; Corticosteroid ; Gadolinium
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Treatment with methylprednisolone reduces the duration and severity of clinical relapses in multiple sclerosis (MS), while reducing the number of gadolinium-enhancing lesions on T1-weighted MRI. We performed serial MRI imaging after methylprednisolone treatment to see whether suppression of enhancement persists and whether related abnormalities on T2-weighted images disappear at follow-up. Thirteen patients with definite MS received a total of 31 courses of methylprednisolone over an average period of 50 weeks. Gadolinium-enhanced MRI was obtained before and after treatment, then at monthly intervals, using a standardised repositioning and imaging protocol. Two experienced readers in conference defined the number of active (gadolinium-enhancing and new or enlarging nonenhancing) lesions. We detected 609 active lesions on 195 examinations. Directly after treatment the reduction in the number of enhancing lesions was 78%, indicating restoration of the BBB and suppression of inflammation. It was uncommon for a lesion which stopped enhancing to show enhancement on a subsequent examination. No beneficial effect was observed on the rate of disappearance of related abnormalities on T2-weighted images, indicating persistent change such as oedema, cellular infiltration or demyelination. Moreover, in 89% of cases, an increase in the number of active lesions was observed before new clinical activity, if any, was observed (on average 52% earlier). MRI enabled us to demonstrate that the duration of the effect of methylprednisolone treatment is temporary (on average 9.7 weeks).
Type of Medium:
Electronic Resource
URL:
_version_ 1798295852425412608
autor Barkhof, F.
Tas, M. W.
Frequin, S. T. F. M.
Scheltens, P.
Hommes, O. R.
Nauta, J. J. P.
Valk, J.
autorsonst Barkhof, F.
Tas, M. W.
Frequin, S. T. F. M.
Scheltens, P.
Hommes, O. R.
Nauta, J. J. P.
Valk, J.
book_url http://dx.doi.org/10.1007/BF00612124
datenlieferant nat_lic_papers
hauptsatz hsatz_simple
identnr NLM202546470
issn 1432-1920
journal_name Neuroradiology
materialart 1
notes Abstract Treatment with methylprednisolone reduces the duration and severity of clinical relapses in multiple sclerosis (MS), while reducing the number of gadolinium-enhancing lesions on T1-weighted MRI. We performed serial MRI imaging after methylprednisolone treatment to see whether suppression of enhancement persists and whether related abnormalities on T2-weighted images disappear at follow-up. Thirteen patients with definite MS received a total of 31 courses of methylprednisolone over an average period of 50 weeks. Gadolinium-enhanced MRI was obtained before and after treatment, then at monthly intervals, using a standardised repositioning and imaging protocol. Two experienced readers in conference defined the number of active (gadolinium-enhancing and new or enlarging nonenhancing) lesions. We detected 609 active lesions on 195 examinations. Directly after treatment the reduction in the number of enhancing lesions was 78%, indicating restoration of the BBB and suppression of inflammation. It was uncommon for a lesion which stopped enhancing to show enhancement on a subsequent examination. No beneficial effect was observed on the rate of disappearance of related abnormalities on T2-weighted images, indicating persistent change such as oedema, cellular infiltration or demyelination. Moreover, in 89% of cases, an increase in the number of active lesions was observed before new clinical activity, if any, was observed (on average 52% earlier). MRI enabled us to demonstrate that the duration of the effect of methylprednisolone treatment is temporary (on average 9.7 weeks).
package_name Springer
publikationsjahr_anzeige 1994
publikationsjahr_facette 1994
publikationsjahr_intervall 8009:1990-1994
publikationsjahr_sort 1994
publisher Springer
reference 36 (1994), S. 382-387
schlagwort Multiple sclerosis
Magnetic resonance imaging
Corticosteroid
Gadolinium
search_space articles
shingle_author_1 Barkhof, F.
Tas, M. W.
Frequin, S. T. F. M.
Scheltens, P.
Hommes, O. R.
Nauta, J. J. P.
Valk, J.
shingle_author_2 Barkhof, F.
Tas, M. W.
Frequin, S. T. F. M.
Scheltens, P.
Hommes, O. R.
Nauta, J. J. P.
Valk, J.
shingle_author_3 Barkhof, F.
Tas, M. W.
Frequin, S. T. F. M.
Scheltens, P.
Hommes, O. R.
Nauta, J. J. P.
Valk, J.
shingle_author_4 Barkhof, F.
Tas, M. W.
Frequin, S. T. F. M.
Scheltens, P.
Hommes, O. R.
Nauta, J. J. P.
Valk, J.
shingle_catch_all_1 Barkhof, F.
Tas, M. W.
Frequin, S. T. F. M.
Scheltens, P.
Hommes, O. R.
Nauta, J. J. P.
Valk, J.
Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis
Multiple sclerosis
Magnetic resonance imaging
Corticosteroid
Gadolinium
Multiple sclerosis
Magnetic resonance imaging
Corticosteroid
Gadolinium
Abstract Treatment with methylprednisolone reduces the duration and severity of clinical relapses in multiple sclerosis (MS), while reducing the number of gadolinium-enhancing lesions on T1-weighted MRI. We performed serial MRI imaging after methylprednisolone treatment to see whether suppression of enhancement persists and whether related abnormalities on T2-weighted images disappear at follow-up. Thirteen patients with definite MS received a total of 31 courses of methylprednisolone over an average period of 50 weeks. Gadolinium-enhanced MRI was obtained before and after treatment, then at monthly intervals, using a standardised repositioning and imaging protocol. Two experienced readers in conference defined the number of active (gadolinium-enhancing and new or enlarging nonenhancing) lesions. We detected 609 active lesions on 195 examinations. Directly after treatment the reduction in the number of enhancing lesions was 78%, indicating restoration of the BBB and suppression of inflammation. It was uncommon for a lesion which stopped enhancing to show enhancement on a subsequent examination. No beneficial effect was observed on the rate of disappearance of related abnormalities on T2-weighted images, indicating persistent change such as oedema, cellular infiltration or demyelination. Moreover, in 89% of cases, an increase in the number of active lesions was observed before new clinical activity, if any, was observed (on average 52% earlier). MRI enabled us to demonstrate that the duration of the effect of methylprednisolone treatment is temporary (on average 9.7 weeks).
1432-1920
14321920
Springer
shingle_catch_all_2 Barkhof, F.
Tas, M. W.
Frequin, S. T. F. M.
Scheltens, P.
Hommes, O. R.
Nauta, J. J. P.
Valk, J.
Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis
Multiple sclerosis
Magnetic resonance imaging
Corticosteroid
Gadolinium
Multiple sclerosis
Magnetic resonance imaging
Corticosteroid
Gadolinium
Abstract Treatment with methylprednisolone reduces the duration and severity of clinical relapses in multiple sclerosis (MS), while reducing the number of gadolinium-enhancing lesions on T1-weighted MRI. We performed serial MRI imaging after methylprednisolone treatment to see whether suppression of enhancement persists and whether related abnormalities on T2-weighted images disappear at follow-up. Thirteen patients with definite MS received a total of 31 courses of methylprednisolone over an average period of 50 weeks. Gadolinium-enhanced MRI was obtained before and after treatment, then at monthly intervals, using a standardised repositioning and imaging protocol. Two experienced readers in conference defined the number of active (gadolinium-enhancing and new or enlarging nonenhancing) lesions. We detected 609 active lesions on 195 examinations. Directly after treatment the reduction in the number of enhancing lesions was 78%, indicating restoration of the BBB and suppression of inflammation. It was uncommon for a lesion which stopped enhancing to show enhancement on a subsequent examination. No beneficial effect was observed on the rate of disappearance of related abnormalities on T2-weighted images, indicating persistent change such as oedema, cellular infiltration or demyelination. Moreover, in 89% of cases, an increase in the number of active lesions was observed before new clinical activity, if any, was observed (on average 52% earlier). MRI enabled us to demonstrate that the duration of the effect of methylprednisolone treatment is temporary (on average 9.7 weeks).
1432-1920
14321920
Springer
shingle_catch_all_3 Barkhof, F.
Tas, M. W.
Frequin, S. T. F. M.
Scheltens, P.
Hommes, O. R.
Nauta, J. J. P.
Valk, J.
Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis
Multiple sclerosis
Magnetic resonance imaging
Corticosteroid
Gadolinium
Multiple sclerosis
Magnetic resonance imaging
Corticosteroid
Gadolinium
Abstract Treatment with methylprednisolone reduces the duration and severity of clinical relapses in multiple sclerosis (MS), while reducing the number of gadolinium-enhancing lesions on T1-weighted MRI. We performed serial MRI imaging after methylprednisolone treatment to see whether suppression of enhancement persists and whether related abnormalities on T2-weighted images disappear at follow-up. Thirteen patients with definite MS received a total of 31 courses of methylprednisolone over an average period of 50 weeks. Gadolinium-enhanced MRI was obtained before and after treatment, then at monthly intervals, using a standardised repositioning and imaging protocol. Two experienced readers in conference defined the number of active (gadolinium-enhancing and new or enlarging nonenhancing) lesions. We detected 609 active lesions on 195 examinations. Directly after treatment the reduction in the number of enhancing lesions was 78%, indicating restoration of the BBB and suppression of inflammation. It was uncommon for a lesion which stopped enhancing to show enhancement on a subsequent examination. No beneficial effect was observed on the rate of disappearance of related abnormalities on T2-weighted images, indicating persistent change such as oedema, cellular infiltration or demyelination. Moreover, in 89% of cases, an increase in the number of active lesions was observed before new clinical activity, if any, was observed (on average 52% earlier). MRI enabled us to demonstrate that the duration of the effect of methylprednisolone treatment is temporary (on average 9.7 weeks).
1432-1920
14321920
Springer
shingle_catch_all_4 Barkhof, F.
Tas, M. W.
Frequin, S. T. F. M.
Scheltens, P.
Hommes, O. R.
Nauta, J. J. P.
Valk, J.
Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis
Multiple sclerosis
Magnetic resonance imaging
Corticosteroid
Gadolinium
Multiple sclerosis
Magnetic resonance imaging
Corticosteroid
Gadolinium
Abstract Treatment with methylprednisolone reduces the duration and severity of clinical relapses in multiple sclerosis (MS), while reducing the number of gadolinium-enhancing lesions on T1-weighted MRI. We performed serial MRI imaging after methylprednisolone treatment to see whether suppression of enhancement persists and whether related abnormalities on T2-weighted images disappear at follow-up. Thirteen patients with definite MS received a total of 31 courses of methylprednisolone over an average period of 50 weeks. Gadolinium-enhanced MRI was obtained before and after treatment, then at monthly intervals, using a standardised repositioning and imaging protocol. Two experienced readers in conference defined the number of active (gadolinium-enhancing and new or enlarging nonenhancing) lesions. We detected 609 active lesions on 195 examinations. Directly after treatment the reduction in the number of enhancing lesions was 78%, indicating restoration of the BBB and suppression of inflammation. It was uncommon for a lesion which stopped enhancing to show enhancement on a subsequent examination. No beneficial effect was observed on the rate of disappearance of related abnormalities on T2-weighted images, indicating persistent change such as oedema, cellular infiltration or demyelination. Moreover, in 89% of cases, an increase in the number of active lesions was observed before new clinical activity, if any, was observed (on average 52% earlier). MRI enabled us to demonstrate that the duration of the effect of methylprednisolone treatment is temporary (on average 9.7 weeks).
1432-1920
14321920
Springer
shingle_title_1 Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis
shingle_title_2 Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis
shingle_title_3 Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis
shingle_title_4 Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis
sigel_instance_filter dkfz
geomar
wilbert
ipn
albert
fhp
source_archive Springer Online Journal Archives 1860-2000
timestamp 2024-05-06T09:42:47.730Z
titel Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis
titel_suche Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis
topic WW-YZ
uid nat_lic_papers_NLM202546470